Follicular Lymphoma Clinical Trials in Seattle, Washington

6 studies are recruiting for follicular lymphoma in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Research Center, Seattle, Washington

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

2. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

   The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle, Washington

   Locations

   46 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07226843 on ClinicalTrials.gov

3. A Long-term Extension Study of PCI-32765 (Ibrutinib)

   The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   175 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT01804686 on ClinicalTrials.gov

4. Study of SGR-1505 in Mature B-Cell Neoplasms

   The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   36 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT05544019 on ClinicalTrials.gov

5. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

   The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington-Seattle Cancer Care Alliance, Seattle, Washington

   Locations

   12 in total

   Run by

   Enterome

   See if you can join NCT04669171 on ClinicalTrials.gov

6. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Seattle, Washington

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov